Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 7Ipilimumab 4pembrolizumab 3Interferon alpha-2 3relatlimab 2Drug Therapy 2Dacarbazine 2sargramostim 1salicylhydroxamic acid 1peginterferon alfa-2b 1peginterferon alfa-2a 1molgramostim 1entrectinib 1cyclopropapyrroloindole 1cobimetinib 1atezolizumab 1Vemurafenib 1Triamcinolone Acetonide 1Temozolomide 1Specimen Handling 1Sonazoid 1Ranibizumab 1Propranolol 1Lenalidomide 1Introns 1Immunotherapy 1Imiquimod 1Fatty Acids, Omega-3 1Crizotinib 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Melanoma × Colony-Stimulating Factors × Clear all
NCT02339571 2026-05-29

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡